Guidelines on Stem Cell technology to be released in China

The China Food and Drug Administration recently held a meeting with stem cell experts and announced that the formation of guidelines on the application of stem cells will be concluded during the first half of this year at the earliest, according to the report.
One of the experts said that developing the guidelines should not be difficult because China could refer to those established by the International Society for Stem Cell Research.
An industry insider said China is at the forefront of stem cell research, citing experiments conducted in the 1980s by Wu Zuze, a former head of the Military Academy of Medical Sciences who successfully transplanted fetal liver stem cells in 11 patients. Nine of the patients are still alive today, the newspaper said. But the development of stem cell technology in China has been hampered by a lack of regulation, said the report.
Li Dexing, a research fellow at the Chinese Center of Disease Control and Prevention, suggested, for example, that the Chinese government adopt the "compassionate use exemption" used in the United States in over 300 cases for treatments involving stem cells.
The commercialization of stem cell technology remains in its early stages in China.
According to Zhong Hua, a professor at the Chinese Academy of Medical Science, the sector is currently involved in the collection and storage of stem cells, the development of stem cell technology, and transplants and treatment.